Chemo combination promising for multiple myeloma
For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in the Journal of Clinical Oncology.
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in the Journal of Clinical Oncology.
Sagar Lonial, M.D., of the Winship Cancer Institute at Emory University in Atlanta, and colleagues conducted a phase I study to evaluate the dose-limiting toxicities and response rates associated with elotuzumab, lenalidomide, and low-dose dexamethasone treatment in 28 patients with relapsed or refractory multiple myeloma (median, three prior multiple myeloma therapies). Patients were treated with 5, 10, or 20 mg/kg elotuzumab, plus lenalidomide and dexamethasone.
The researchers found no dose-limiting toxicities up to the maximum 20-mg/kg dose of elotuzumab. Neutropenia (36 percent) and thrombocytopenia (21 percent) were the most frequently reported grade 3 or 4 toxicities. Two serious infusion reactions, including one grade 4 anaphylactic reaction and one grade 3 stridor, occurred in two patients during the first treatment cycle. A total of 82 percent of patients exhibited objective responses. For patients treated until disease progression, after a median of 16.4 months follow-up, the median time to progression was not reached for patients in the 20-mg/kg cohort.
"The combination of elotuzumab, lenalidomide, and dexamethasone appears to be active, with results from this phase I study suggesting enhanced efficacy over lenalidomide and low-dose dexamethasone alone," the authors write. "Further validation of the dose, safety, and efficacy in larger patient populations is warranted and underway."
More information: doi: 10.1200/JCO.2011.37.2649
Journal reference:
Journal of Clinical Oncology
Copyright © 2012 HealthDay. All rights reserved.
-
Multiple myeloma clinical trial closes early
Apr 05, 2007 |
not rated yet |
0
-
Drug combination improves or stabilizes disease for relapsed multiple myeloma patients
Dec 09, 2008 |
not rated yet |
0
-
Drug combination shows promise for newly diagnosed blood cancer patients, study finds
Dec 09, 2010 |
not rated yet |
0
-
High response rates seen in phase-III trial of chemotherapy, new drug and stem cells in myeloma
Oct 12, 2010 |
not rated yet |
0
-
New myeloma drug shows promise in early testing
Jun 07, 2010 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
13 hours ago
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Research identifies a way to make cancer cells more responsive to chemotherapy
Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...
Cancer
9 minutes ago |
not rated yet |
0
Mayo Clinic genomic analysis lends insight to prostate cancer
Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...
Cancer
13 minutes ago |
not rated yet |
0
When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs
Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...
Cancer
1 hour ago |
not rated yet |
0
|
Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...
Cancer
5 hours ago |
not rated yet |
0
Protein preps cells to survive stress of cancer growth and chemotherapy
Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.
Cancer
5 hours ago |
not rated yet |
0
|
Shortage of key drug hampering U.S. efforts to control TB, report says
(HealthDay)—A shortage of a critical tuberculosis drug has hampered the efforts of health departments across the United States to contain the spread of the highly infectious lung disease, federal officials ...
Heart healthy lifestyle may cut kidney disease patients' risk of kidney failure
Maintaining a heart healthy lifestyle may also help protect chronic kidney disease patients from developing kidney failure and dying prematurely, according to a study appearing in an upcoming issue of the Journal of the Am ...
New microsphere-based methods for detecting HIV antibodies
Detection of HIV antibodies is used to diagnose HIV infection and monitor trials of experimental HIV/AIDS vaccines. New, more sensitive detection systems being developed use microspheres to capture HIV antibodies ...
It's not your imagination: Memory gets muddled at menopause
Don't doubt it when a woman harried by hot flashes says she's having a hard time remembering things. A new study published online in Menopause, the journal of The North American Menopause Society (NAMS), helps confirm with o ...
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Farm bill: Senate rejects GMO labeling amendment
The Senate has overwhelmingly rejected an amendment allowing states to require labeling of genetically modified foods.